CASSIPA Trademark

Trademark Overview


On Monday, October 1, 2018, a trademark application was filed for CASSIPA with the United States Patent and Trademark Office. The USPTO has given the CASSIPA trademark a serial number of 88138274. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, June 6, 2022. This trademark is owned by Acttavis Holdco US, Inc.. The CASSIPA trademark is filed in the Pharmaceutical Products category with the following description:

Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines affecting sensory organs; Pharmaceuticals and medicines affecting the central nervous system; Pharmaceuticals a...
cassipa

General Information


Serial Number88138274
Word MarkCASSIPA
Filing DateMonday, October 1, 2018
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, June 6, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 5, 2019

Trademark Statements


Goods and ServicesOral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines affecting sensory organs; Pharmaceuticals and medicines affecting the central nervous system; Pharmaceuticals and medicines affecting urogenital organs; Pharmaceuticals and medicines affecting circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression, neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, October 9, 2018
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameActtavis Holdco US, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Party NameActtavis Holdco US, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Trademark Events


Event DateEvent Description
Monday, June 6, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, June 6, 2022ABANDONMENT - NO USE STATEMENT FILED
Wednesday, November 3, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, November 2, 2021SOU EXTENSION 5 GRANTED
Thursday, October 28, 2021SOU EXTENSION 5 FILED
Thursday, October 28, 2021TEAS EXTENSION RECEIVED
Saturday, May 1, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, April 29, 2021SOU EXTENSION 4 GRANTED
Thursday, April 29, 2021SOU EXTENSION 4 FILED
Thursday, April 29, 2021TEAS EXTENSION RECEIVED
Thursday, October 8, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, October 6, 2020SOU EXTENSION 3 GRANTED
Tuesday, October 6, 2020SOU EXTENSION 3 FILED
Tuesday, October 6, 2020TEAS EXTENSION RECEIVED
Saturday, May 2, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, April 30, 2020SOU EXTENSION 2 GRANTED
Thursday, April 30, 2020SOU EXTENSION 2 FILED
Thursday, April 30, 2020TEAS EXTENSION RECEIVED
Tuesday, January 14, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, January 13, 2020SOU EXTENSION 1 GRANTED
Wednesday, October 30, 2019SOU EXTENSION 1 FILED
Monday, January 13, 2020CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, December 4, 2019NOTICE OF REVIVAL - E-MAILED
Tuesday, December 3, 2019EXTENSION RECEIVED WITH TEAS PETITION
Tuesday, December 3, 2019PETITION TO REVIVE-GRANTED
Tuesday, December 3, 2019TEAS PETITION TO REVIVE RECEIVED
Monday, December 2, 2019ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, December 2, 2019ABANDONMENT - NO USE STATEMENT FILED
Tuesday, April 30, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, March 5, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 5, 2019PUBLISHED FOR OPPOSITION
Wednesday, February 13, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, January 18, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, January 11, 2019ASSIGNED TO EXAMINER
Tuesday, October 9, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, October 4, 2018NEW APPLICATION ENTERED IN TRAM